We hypothesize this is because CD4+ anti-TGF-β CAR T cells lysed cancer cells, prevented exhaustion of CD8+ conventional CAR T cells, and improved the CD8+ conventional CAR T cells’ efficacy. The gene discussed is TGFB1; the disease is cancer.